63204-32-0

Basic information

• Product Name: 4(1H)-Pyrimidinone, 5-[(3-chlorophenyl)methyl]-2,3-dihydro-2-thioxo-
• CAS NO: 63204-32-0
• Molecular Formula: C11H9ClN2OS
• Molecular Weight: 252.724
• Mol File: 63204-32-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4(1H)-Pyrimidinone, 5-[(3-chlorophenyl)methyl]-2,3-dihydro-2-thioxo-(CAS DataBase Reference)
• NIST Chemistry Reference: 4(1H)-Pyrimidinone, 5-[(3-chlorophenyl)methyl]-2,3-dihydro-2-thioxo-(63204-32-0)
• EPA Substance Registry System: 4(1H)-Pyrimidinone, 5-[(3-chlorophenyl)methyl]-2,3-dihydro-2-thioxo-(63204-32-0)

Safety Data

• Hazardous Substances Data: 63204-32-0(Hazardous Substances Data)

Upstream product

• 17356-08-0 thiourea 
• 7116-35-0 ethyl 3-(3-chlorophenyl)propanoate 
• 109-94-4 formic acid ethyl ester 
• 1866-38-2 3-chlorocinnamic acid 
• 2373-88-8 3-(3-chloro-phenyl)-acrylic acid ethyl ester 
• 2373-88-8 ethyl (E)-3-(3-chlorophenyl)prop-2-enoate 
• 587-04-2 m-Chlorobenzaldehyde 
• 7440-23-5 sodium 

Downstream Products

• 63204-33-1 5-(3-chlorobenzyl)-2-methylthio-4-pyrimidone 
• 156176-38-4 5-(3-Chloro-benzyl)-1H-pyrimidine-2,4-dione 
• 63204-15-9 2-[2-(5-Methyl-4-imidazolylmethylthio)ethylamino]-5-(3-chlorobenzyl)-4-pyrimidone dihydrochloride 
• 1027018-75-2 C₂₉H₂₅ClN₂O₇ 
• 156176-25-9 Acetic acid 2-[5-(3-chloro-benzyl)-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethoxy]-ethyl ester 

Relevant articles and documents

Inhibition of uridine phosphorylase: Synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2- hydroxyethoxy)methyl]-5-benzyluracils

A series of 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils were synthesized and tested for inhibition of murine liver uridine phosphorylase (UrdPase). Inhibitors of UrdPase are reported to enhance the chemotherapeutic utility of 5-fluoro-2'-deoxyuridine and 5-fluorouracil and to ameliorate zidovudine- induced anemia in animal models. We prepared a series of 5-aryl-substituted analogues of 5-benzylacyclouridine (BAU), a good inhibitor of UrdPase (IC50 of 0.46 μM), to develop a compound with enhanced potency and improved pharmacokinetics. The first phase of structure-activity relationship studies on a series of 32 aryl-substituted 5-benzyluracils found several 5-(3- alkoxybenzyl) analogues of 5-benzyluracil with enhanced potency. The acyclovir side chain, the (2-hydroxyethoxy)methyl group, was substituted on the more potent aryl-substituted 5-benzyluracils. The two most potent compounds, 10y (3-propoxy) and 10dd (3-sec-butoxy), were inhibitors of UrdPase with IC50s of 0.047 and 0.027 μM, respectively. Six compounds were tested in vivo for effects on steady-state concentrations of circulating uridine in rats. Plasma uridine levels were elevated 3-9-fold by compound levels that ranged from 8 to 50 μM.

4-PYRIMIDONE COMPOUNDS

The compounds are substituted isocytosines which are histamine H 2-antagonists. Two specific compounds of the present invention are 2-2-(5-methyl-4-imidazolylmethylthio)-ethylamino!-5-(3-methoxybenzyl)-4-pyrim idone and 2-2-(5-methyl-4-imidazolylmethylthio)ethylamino!-5-benzyloxy-4-pyrimidone.